TPST Tempest Therapeutics, Inc.

Tempest Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Seeks to create distinct and transformative treatments where there is a significant unmet medical need.

$3.86  -0.05 (-1.28%)
As of 05/26/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/24/2021
Outstanding shares:  10,323,006
Average volume:  224,807
Market cap:   $40,362,953
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.74
PS ratio:   0.00
Return on equity:   -96.75%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy